Sunshine Financial Statements From 2010 to 2026

Stocks . USA . 
Stock . Sunshine Biopharma
SBFM Stock  USD 1.23  0.01  0.82%   
Sunshine Biopharma's financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Sunshine Biopharma's valuation are provided below:
Gross Profit
12.1 M
Profit Margin
(0.17)
Market Capitalization
8.2 M
Enterprise Value Revenue
39.4772
Revenue
36.3 M
There are over one hundred nineteen available fundamental trend indicators for Sunshine Biopharma, which can be analyzed over time and compared to other ratios. Self-guided Investors are advised to double-check Sunshine Biopharma's current fundamentals against the trend between 2010 and 2026 to make sure the company can sustain itself down the road.

Sunshine Biopharma Total Revenue

42.11 Million

Check Sunshine Biopharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Sunshine Biopharma's main balance sheet or income statement drivers, such as Interest Expense of 9.6 K, Other Operating Expenses of 49.1 M or Total Operating Expenses of 19.9 M, as well as many indicators such as Price To Sales Ratio of 0.066, Dividend Yield of 0.0 or PTB Ratio of 0.0979. Sunshine financial statements analysis is a perfect complement when working with Sunshine Biopharma Valuation or Volatility modules.
  
Build AI portfolio with Sunshine Stock
Check out the analysis of Sunshine Biopharma Correlation against competitors.
To learn how to invest in Sunshine Stock, please use our How to Invest in Sunshine Biopharma guide.

Sunshine Biopharma Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets36.9 M35.1 M9.7 M
Slightly volatile
Total Current Liabilities7.6 M7.3 M2.3 M
Slightly volatile
Accounts Payable6.7 M6.4 M1.4 M
Slightly volatile
Cash11.7 M11.1 M4.4 M
Slightly volatile
Cash And Short Term Investments11.7 M11.1 M4.4 M
Slightly volatile
Common Stock Shares Outstanding847.4 K807 K144.3 K
Slightly volatile
Liabilities And Stockholders Equity36.9 M35.1 M9.7 M
Slightly volatile
Non Current Liabilities Total517.6 K856.4 K576.2 K
Slightly volatile
Other Stockholder Equity112.7 M107.4 M36 M
Slightly volatile
Total Liabilities8.5 M8.1 M2.8 M
Slightly volatile
Total Current Assets31.4 M29.9 M8.4 M
Slightly volatile
Common Stock2.8 K3 K136.1 K
Pretty Stable
Short and Long Term Debt Total780.2 K1.1 M738 K
Slightly volatile
Other Current Liabilities498.2 K340.2 K450.9 K
Slightly volatile
Other Assets97 K92.3 K77.3 K
Slightly volatile
Other Current Assets1.4 M1.3 M323.6 K
Slightly volatile
Short Term Debt227 K238.9 K464.3 K
Pretty Stable
Short and Long Term Debt4.4 M4.2 M1.7 M
Slightly volatile
Property Plant And Equipment Net1.8 M1.7 M444.9 K
Slightly volatile
Non Current Assets Total5.5 M5.3 M1.5 M
Slightly volatile
Net Receivables4.7 M4.4 M1 M
Slightly volatile
Property Plant Equipment7.7 K8.1 K13.7 K
Very volatile
Long Term Debt2.3 M2.2 M876.8 K
Slightly volatile
Other Liabilities36.8 K38.7 K173.1 K
Slightly volatile
Current Deferred Revenue192.1 K344.8 K163.5 K
Slightly volatile
Good Will532.6 K599.1 K653.9 K
Slightly volatile
Capital Stock13.3 K14 K114.7 K
Slightly volatile
Short Term Investments6.1 K6.8 K7.5 K
Slightly volatile
Property Plant And Equipment Gross2.2 M2.1 M547.1 K
Slightly volatile

Sunshine Biopharma Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Interest Expense9.6 K10.1 K128.3 K
Slightly volatile
Other Operating Expenses49.1 M46.8 M11.3 M
Slightly volatile
Total Operating Expenses19.9 M19 M5.4 M
Slightly volatile
Selling General Administrative16.9 M16.1 M4.5 M
Slightly volatile
Selling And Marketing Expenses1.1 M1.1 M567.4 K
Slightly volatile
Depreciation And Amortization303.9 K201.2 K402.9 K
Slightly volatile
Cost Of Revenue29.2 M27.8 M6 M
Slightly volatile
Non Recurring106.5 K68.3 K136 K
Slightly volatile
Reconciled Depreciation269.9 K257.1 K61.4 K
Slightly volatile

Sunshine Biopharma Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Cash From Financing Activities11.2 M10.7 M4.9 M
Slightly volatile
End Period Cash Flow11.7 M11.1 M4.4 M
Slightly volatile
Begin Period Cash Flow19.7 M18.7 M4.7 M
Slightly volatile
Depreciation269.9 K257.1 K65.2 K
Slightly volatile
Change To Netincome22.1 M21.1 M7.3 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio0.0660.0694164.4 K
Slightly volatile
Days Sales Outstanding44.2346.56257
Slightly volatile
Average Payables3.8 M3.7 M1.2 M
Slightly volatile
Stock Based Compensation To Revenue4.394.6226.586
Slightly volatile
Capex To Depreciation21.4611.9456.1546
Slightly volatile
Payables Turnover4.775.0278.0369
Slightly volatile
Sales General And Administrative To Revenue0.440.46162
Slightly volatile
Research And Ddevelopement To Revenue0.02930.03082.0802
Slightly volatile
Capex To Revenue0.07270.0765129
Slightly volatile
Cash Per Share11.812.421.7 K
Very volatile
Days Payables Outstanding71.4775.23374
Pretty Stable
Income Quality2.312.20.7638
Slightly volatile
Intangibles To Total Assets0.110.09880.4529
Slightly volatile
Current Ratio6.644.735.5156
Pretty Stable
Receivables Turnover9.8510.3718.0752
Pretty Stable
Capex Per Share3.613.8230
Slightly volatile
Average Receivables2.1 M2 M844.3 K
Slightly volatile
Revenue Per Share42.4944.73180
Slightly volatile
Debt To Assets0.03410.03581.6183
Slightly volatile
Days Of Payables Outstanding71.4775.23374
Pretty Stable
Ebt Per Ebit1.630.831.819
Pretty Stable
Quick Ratio2.542.674.8898
Pretty Stable
Net Income Per E B T1.231.11.0876
Pretty Stable
Cash Ratio1.681.763.866
Pretty Stable
Days Of Sales Outstanding44.2346.56257
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.231.361.3148
Slightly volatile
Fixed Asset Turnover22.2421.188.1482
Slightly volatile
Debt Ratio0.03410.03581.6183
Slightly volatile
Price Sales Ratio0.0660.0694164.4 K
Slightly volatile
Asset Turnover1.081.030.3442
Slightly volatile

Sunshine Biopharma Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap339.9 K382.4 K417.4 K
Slightly volatile
Enterprise Value483.5 K544 K593.7 K
Slightly volatile

Sunshine Fundamental Market Drivers

Sunshine Upcoming Events

2nd of April 2024
Upcoming Quarterly Report
View
31st of December 2023
Next Fiscal Quarter End
View

About Sunshine Biopharma Financial Statements

Sunshine Biopharma investors utilize fundamental indicators, such as revenue or net income, to predict how Sunshine Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue344.8 K192.1 K
Cost Of Revenue27.8 M29.2 M
Total Revenue40.1 M42.1 M
Stock Based Compensation To Revenue 4.62  4.39 
Sales General And Administrative To Revenue 0.46  0.44 
Research And Ddevelopement To Revenue 0.03  0.03 
Capex To Revenue 0.08  0.07 
Revenue Per Share 44.73  42.49 
Ebit Per Revenue(0.15)(0.16)

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Prophet is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Prophet
When determining whether Sunshine Biopharma is a strong investment it is important to analyze Sunshine Biopharma's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Sunshine Biopharma's future performance. For an informed investment choice regarding Sunshine Stock, refer to the following important reports:
How To Invest In Sunshine
Details
Is Sunshine Stock a good investment?
Details
What is Sunshine Biopharma's Net Worth?
Details
Largest Biotechnology Companies
View
Largest Pharmaceuticals, Biotechnology & Life Sciences Companies
View
Check out the analysis of Sunshine Biopharma Correlation against competitors.
To learn how to invest in Sunshine Stock, please use our How to Invest in Sunshine Biopharma guide.
You can also try the Pattern Recognition module to use different Pattern Recognition models to time the market across multiple global exchanges.
Will Biotechnology sector continue expanding? Could Sunshine diversify its offerings? Factors like these will boost the valuation of Sunshine Biopharma. If investors know Sunshine will grow in the future, the company's valuation will be higher. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Sunshine Biopharma data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share
(15.02)
Revenue Per Share
14.633
Quarterly Revenue Growth
0.012
Return On Assets
(0.11)
Return On Equity
(0.26)
Investors evaluate Sunshine Biopharma using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Sunshine Biopharma's intrinsic value—the estimated true worth—helps identify when the stock trades at a discount or premium to fair value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. External factors like market trends, sector rotation, and investor psychology can cause Sunshine Biopharma's market price to deviate significantly from intrinsic value.
Altman
Z Score
Details
Piotroski
F Score
Details
Beneish
M Score
Details
Financial
Analysis
Details
Buy or Sell
Advice
Details
Earnings
Projections
Details
Please note, there is a significant difference between Sunshine Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Sunshine Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. Conversely, Sunshine Biopharma's market price signifies the transaction level at which participants voluntarily complete trades.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY